ライフサイエンスコーパス: cold ischemia time

1 ntigen mismatch, pretransplant dialysis, and cold ischemia time.

2 g donor type, HLA mismatches, donor age, and cold ischemia time.

3 ale donor, PRA as a continuous variable, and cold ischemia time.

4 n of CD14 mRNA correlated with the length of cold ischemia time.

5 diate-term graft survival despite increasing cold ischemia time.

6 nsitized patients in spite of similar length cold ischemia time.

7 prevalent in cadaveric allografts with long cold ischemia time.

8 variables included age, weight, gender, and cold ischemia time.

9 ps in terms of recipient sex, race, age, and cold ischemia time.

10 sical crossmatch and has potential to reduce cold ischemia time.

11 ard or delayed allocation beyond 36 hours of cold ischemia time.

12 er cardiac death status, cause of death, and cold ischemia time.

13 th University of Wisconsin solution and 6-hr cold ischemia time.

14 al donors (n = 14) matched for age, BMI, and cold ischemia time.

15 ate pathology in allografts with 0.5 hour of cold-ischemia time.

16 l with donor BMI >30 (P=0.06) and increasing cold-ischemia time.

17 om older, more mismatched donors with longer cold ischemia times.

18 seen in grafts from older donors and longer cold ischemia times.

19 nce of delayed graft function (38% vs. 26%), cold ischemia times (12.9 vs. 13.5 hr), and graft surviv

20 of HAT was 8 out of 73 transplants (11%).The cold ischemia time (14.3 +/- 3.03 hr) in this group was

21 thotopic liver transplantation with extended cold ischemia time (18 h).

22 wait-time (571 vs. 471 days, P<0.01), longer cold ischemia time (22 vs. 20 hr, P<0.01), and donor and

23 (100% vs. 40% and 46%, p < .01) with longer cold ischemia times (25.2 h vs. 22.9 h and 22.2 h, p = .

24 ed with recipients of kidneys with a shorter cold ischemia time (3.2%).

25 being from donors after brain death (median cold ischemia time 33 +/- 36.9 hours) and 5 being from d

26 l group, kidneys with diffuse GFT had longer cold ischemia time (34 versus 27 h), were more frequentl

27 We found that a prolonged cold ischemia time (6-12 hr) alone did not induce IE.

28 age Liver Disease score was 15 (IQR, 11-21); cold ischemia time, 8.0 hours (IQR, 6.4-9.7 hours); MEAF

29 levels of panel-reactive antibodies, shorter cold ischemia times, a lower incidence of delayed graft

30 Increased donor age and cold ischemia time additionally decreased graft survival

31 ble to the effect of each hour of additional cold ischemia time (adjusted HR 1.04, 95% CI 1.02-1.05;

32 ed with DDK with non-DGF after adjusting for cold ischemia time (alpha=0.001).

33 ations of kidneys with less than 12 hours of cold ischemia time and 74,997 dollars for those with mor

34 There was a significant reduction in cold ischemia time and a decreased rate of pancreatic th

35 ible donors, and is associated with a longer cold ischemia time and a potentially higher rejection ra

36 xidative stress levels, interactions between cold ischemia time and alanine aminotransferase level an

37 fsky score) and donor organ characteristics (cold ischemia time and donor age).

38 risk factors for reduced graft survival are cold ischemia time and donor age.

39 Longer cold ischemia time and large droplet macrovesicular stea

40 Longer cold ischemia time and large droplet macrovesicular stea

41 uld be reallocated without delay to minimize cold ischemia time and maximize the utility of the graft

42 We found a significant increase in cold ischemia time and organs with donor warm ischemia t

43 for the standard FXM, potentially shortening cold ischemia time and providing clinicians with unambig

44 with intrahepatic strictures, and prolonged cold ischemia time and rejection were associated with st

45 When results were adjusted for cold ischemia time and sex, iNO significantly decreased

46 Non-treated allogeneic grafts without cold ischemia time and syngeneic grafts did not develop

47 The short tolerable cold ischemia time and the importance of other risk fact

48 prospective cross-match as a means to reduce cold ischemia time and the incidence of delayed graft fu

49 and the impact of virtual crossmatch use on cold ischemia time and transplant outcomes.

50 Prolonged cold ischemia time and use of a whole graft with recipie

51 nal allocation variance designed to minimize cold ischemia times and encourage adoption of DCD protoc

52 ave focused on graft damage due to prolonged cold ischemia times and rewarming during the long benchi

53 early allograft dysfunction with increasing cold ischemia times and should be transplanted within 12

54 iated with early transplant stressors (e.g., cold ischemia time) and donor aging.

55 antibody titer, extent of HLA matching, and cold-ischemia time), and post-transplantation variables

56 ly significant factors such as HLA mismatch, cold ischemia time, and African-American or diabetic rec

57 ominal sepsis) and donor factors (donor age, cold ischemia time, and donor cytomegalovirus status), m

58 , human leukocyte antigen-B and DR mismatch, cold ischemia time, and double or en bloc transplant.

59 ransplanted, increment of insulin secretion, cold ischemia time, and exocrine tissue volume transplan

60 size, age of donor kidney, damage caused by cold ischemia time, and mode of donor death all had subs

61 T, intraoperative packed red blood cell use, cold ischemia time, and preoperative mechanical ventilat

62 losclerosis, the Kidney Donor Profile Index, cold ischemia time, and recipient age, body mass index,

63 t to include both nonimmunologic (donor age, cold ischemia time, and recipient race) and immunologic

64 assessment of organ quality, complex donors, cold ischemia time, and risks of broken chains.

65 RA), recipient and donor race and donor age, cold ischemia time, and the pretransplantation use of ei

66 ats that received a liver graft with a 16-hr cold ischemia time, and the survival rate was 83% after

67 he effects of this system on graft survival, cold ischemia time, and the transplantation of highly se

68 y, donor and recipient age, body mass index, cold ischemia time, and time to procurement after primar

69 thnicity, cause of liver disease, donor age, cold ischemia time, and waiting time.

70 and acute rejection; and donor age and race, cold ischemia time, and year of transplant.

71 r deceased donor), number of HLA mismatches, cold ischemia time, and year of transplantation.

72 Improved patient selection and reduction in cold ischemia time appear to be contributing factors.

73 Bilirubin and cold ischemia time are crucial for graft outcome post-LT

74 n those retrieved from cadaver donors, where cold ischemia times are significantly longer.

75 , African American ethnicity, donor age, and cold ischemia time as predictors of graft and patient su

76 , older donor age, male donors, and a longer cold ischemia time but not donor terminal creatinine wer

77 age Liver Disease score, and longer warm and cold ischemia times (C statistic, 0.75).

78 dictors, whereas donor age, gender and race, cold ischemia time, cadaveric versus living donor, delay

79 ), but this risk was limited to kidneys with cold ischemia time (CIT) >12 hours.

80 001), non-AA donor (HR 1.66, P < 0.001), and cold ischemia time (CIT) (HR 1.03 per hour >8 hours, P =

81 0.001) and kidneys with longer than 30 hr of cold ischemia time (CIT) (OR, 0.95; per 5% increment; 95

82 Prolonged cold ischemia time (CIT) affected BT rate significantly

83 Studies have shown an increase in cold ischemia time (CIT) after KAS250 implementation but

84 aimed to understand the association between cold ischemia time (CIT) and delayed graft function (DGF

85 zed complement related genes correlated with cold ischemia time (CIT) and markers of inflammation.

86 clinical findings, suboptimal biopsies, long cold ischemia time (CIT) and/or poor hypothermic perfusi

87 Cadaveric kidneys experiencing longer cold ischemia time (CIT) are associated with higher leve

88 We used cold ischemia time (CIT) as an instrument to test the hy

89 Cumulative recurrence curves according to cold ischemia time (CIT) at 2-hour intervals and warm is

90 While the current maximum cold ischemia time (CIT) for donor lungs in clinical LTx

91 en the Kidney Donor Profile Index (KDPI) and cold ischemia time (CIT) in recipients of deceased donor

92 Prolonged cold ischemia time (CIT) is associated with a significan

93 Prolonged cold ischemia time (CIT) is well known to increase graft

94 as 4% (40) and in multivariate analysis only cold ischemia time (CIT) longer than 8 hours (hazard rat

95 ptimizing "modifiable risk factors," such as cold ischemia time (CIT) recipient warm ischemia time (W

96 Cold ischemia time (CIT) was 10.8 +/- 4.1 hours and anas

97 The potential exists for an increase in cold ischemia time (CIT) with resulting increases in del

98 d discards, donor-recipient characteristics, cold ischemia time (CIT), and delayed graft function (DG

99 The effect of this policy on cold ischemia time (CIT), delayed graft function (DGF),

100 covariates in both groups, while donor race, cold ischemia time (CIT), female to male transplants, an

101 Imported pancreata accumulate cold ischemia time (CIT), limiting utilization and worse

102 estigated in addition to causes of prolonged cold ischemia time (CIT).

103 or age, donor warm ischemia time (DWIT), and cold ischemia time (CIT).

104 percentage of transplanted ECD kidneys with cold ischemia times (CIT) <12 hr increased significantly

105 regional perfusion (NRP), and involves short cold ischemia times (CIT) and constrained asystole times

106 Concerns remain over prolonged cold ischemia times (CIT) associated with shipping kidne

107 on for short (3 hr; control) or long (18 hr) cold ischemia times (CIT).

108 ction criteria and the requirement for short cold-ischemia time (CIT).

109 phenomena, such as donor death and possibly cold ischemia time, contributed to differences in comple

110 were used to measure the relationships among cold ischemia time, delayed graft function, acute reject

111 ntibody more than 0%, cytomegalovirus D+/R-, cold ischemia time, delayed graft function, induction wi

112 Primary outcomes were discard, cold-ischemia time, delayed graft function, and 1-year g

113 ansplantation model grafts subjected to long cold ischemia time developed severe TV with intimal hype

114 60 post-transplant, allografts with a 6 hour cold-ischemia time developed extensive glomerular injury

115 erences, including donor brain death, longer cold ischemia time, diabetogenic immunosuppression, and

116 owed no-flow time, functional warm time, and cold ischemia time did not affect the risk of PNF or poo

117 No significant differences in donor age, cold ischemia time, digestion time, or weight of the pan

118 e, panel-reactive antibody level, HLA match, cold ischemia time, donor age, and expanded criteria don

119 stics revealed significant correlations with cold ischemia time, donor age, and renal flow.

120 Cold ischemia times, donor age, and preoperative eGFR fo

121 umber of perfusate platelets correlated with cold ischemia time duration and were indicative for the

122 Cadaveric transplants, prolonged cold ischemia time, elevated panel reactive antibody, an

123 ), expanded criteria donor kidney (15%), and cold ischemia time exceeding 24 hr (27%).

124 l operating room time (207 vs. 200 min.), or cold ischemia time (excluding pancreas).

125 The mean cold ischemia time for both groups was 11 +/-3 hr.

126 in start of surgery (25 vs. 77 min), shorter cold ischemia time for recovered pancreases (355 vs. 630

127 years (range, 1.0-50.0 years), and the mean cold ischemia time for the cadaveric kidneys was 27.0+/-

128 this group was significantly longer than the cold ischemia time for those without HAT (11.7 +/- 3.94

129 with donor body mass index >30 and pancreas cold ischemia time greater than 12 hr.

130 Recipients of kidneys with cold ischemia time greater than 24 hr also had a higher

131 For CAD kidney recipients, organ cold ischemia time greater than 24 hr increased the risk

132 tigen (HLA) mismatches, increased donor age, cold ischemia time greater than 24 hr, African American

133 xplant, donor age greater than 55 years, and cold ischemia time greater than 550 minutes were signifi

134 ican race, Kidney Donor Profile Index > 50%, cold ischemia time > 24 hours) and low-risk (not having

135 HTLV reactive, donation after cardiac death, cold ischemia time >12 hours, ICU stay >5 days, 3 or mor

136 DGF was associated with cold ischemia time >24 hr (P = 0.0003) and Rej (P = 0.06

137 s: donor age >55 yr, non-heartbeating donor, cold ischemia time >36 h, and donor hypertension or diab

138 (>55 years), donor hospital stay (>5 days), cold ischemia time (>10 hours), and warm ischemia time (

139 ithin 3 months posttransplant were prolonged cold ischemia time (>36 hours, odds ratio [OR]=3.38 vs.

140 ree of sensitization, retransplantation, and cold ischemia time; however, EBK recipients were somewha

141 icant correlation between apoptosis rate and cold ischemia time in CAD (r=0.86, P<0.001) renal allogr

142 10) that received a liver graft with a 16-hr cold ischemia time in Euro-Collins solution survived for

143 3+/-14.6 years (range: 0.7-50), and the mean cold ischemia time in the cadaveric cases was 26.5+/-8.8

144 Older recipient age and prolonged cold ischemia time increase the risk of graft failure.

145 Cold ischemia times increased ( P < 0.001); however, the

146 facilities emerged in donor selection (age, cold ischemia time, intensive care unit length, amylase

147 However, when cold ischemia time is longer than 6 h, N-acetylcysteine

148 iver, and only 3% were listed as requiring a cold ischemia time less than 6 hours.

149 matches, human leukocyte antigen antibodies, cold ischemia time, living donor, and preemptive transpl

150 he benefits of sustained euglycemia, shorter cold ischemia times, lower rates of sensitization, and e

151 s were significantly associated with shorter cold ischemia times (mean 15.0 vs 16.5 hours) and simila

152 There was no difference regarding cold ischemia time, model for end-stage liver disease sc

153 95% CI 1.23-2.02, P<0.001), and kidneys with cold ischemia time more than 24 hr (HR 1.31, 95% CI 1.04

154 95% CI 1.20-1.30, P=0.002) and kidneys with cold ischemia time more than 24 hr (HR 1.44, 95% CI 1.04

155 y OPOs to limit nonutilization due to excess cold ischemia time, more than doubled in frequency betwe

156 assessed using this technique after a median cold ischemia time of 13 h 19 min.

157 d kidney donors was 43 years with an average cold ischemia time of 37 hours.

158 SSI: kidney from extended criteria donors, a cold ischemia time of more than 30 hr, time of surgical

159 es, including those of cadaveric grafts with cold ischemia times of as long as 41 hr.

160 The cold-ischemia time of the donor hand was 310 minutes.

161 was unassociated with 0Pre biopsy findings, cold ischemia time, or peak PT values.

162 There was no difference in donor age, cold ischemia time, or recipient United Network for Orga

163 groups in recipient demographics, donor age, cold ischemia time, or total number of doses of Thymoglo

164 r wait times can impact logistics as well as cold ischemia time; our findings motivate an exploration

165 d a reduction in use of donors with extended cold ischemia time (p = 0.04) and private pay recipients

166 Bilirubin (P=0.006) and cold ischemia time (P=0.002) were predictive of graft lo

167 ting for recipient age, sex, race, diabetes, cold ischemia time, panel cross-reactivity, pretransplan

168 Short cold ischemia time, perfusion device use, and the absenc

169 ties for planning surgery and also decreases cold ischemia time, potentially translating into a highe

170 pancreas after kidney recipients, prolonged cold-ischemia time, prolonged donor hypotension, non-hea

171 A negative association to DeltaCP/GCr was cold ischemia time (r=-0.330, P<0.001).

172 , local origin of procurement team, pancreas cold ischemia time, recipient cerebrovascular disease.

173 vailability and thereby increase donor organ cold ischemia time that might then result in increased r

174 in the U.S. study had a significantly longer cold ischemia time (the time elapsed between procurement

175 r 120 min (30-min warm ischemia time, 90-min cold ischemia time), the second kidney was removed (NHBD

176 Assuming no change is cold ischemia time, the potential number of 0 CREG, 0 DR

177 ring of 0-MM kidneys significantly increased cold ischemia time, the risk of graft loss was significa

178 l reactive antibody, delayed graft function, cold ischemia time, time since start of dialysis, etiolo

179 enal grafts were transplanted with a shorter cold ischemia time to more poorly HLA-matched recipients

180 es type, human leukocyte-antigen mismatches, cold ischemia time, transplant era, preemptive transplan

181 es in donor/recipient case-mix and increased cold ischemia times under the Kidney Allocation System (

182 after adjusting for recipient and donor age, cold ischemia time, urine output, and Scr.

183 Within this range of cold ischemia time, UW and HTK demonstrate similar effic

184 Mean kidney cold ischemia time was 10 +/- 3 and 50 +/- 15 hours, for

185 Cold ischemia time was 10.8 +/- 4.1 hours and anastomosi

186 Median cold ischemia time was 103 minutes (range: 93-207 minute

187 The median cold ischemia time was 12 h 30 min (range 5 h 25 min-18

188 yte antigen (HLA) match was one; and average cold ischemia time was 12 hours.

189 In the marginal group, the cutoff value of cold ischemia time was 12.6 hr.

190 Median (range) cold ischemia time was 13.2 (5.1-28.7) hours in the end-

191 Cold ischemia time was 13.6 +/- 4.7 hours; anastomosis t

192 Mean cold ischemia time was 14 hours.

193 Mean cold ischemia time was 26.9+/-8.6 hr.

194 In cadaveric grafts, the mean cold ischemia time was 29.0 hours +/- 6.9 in those with

195 The mean cold ischemia time was 30.5+/-9.2 hr.

196 pancreatic excision was 34 minutes, whereas cold ischemia time was 6 hours and 40 minutes.

197 Mean (SD) cold ischemia time was 6.4 (2.3) h; mean (SD) total pres

198 Mean cold ischemia time was 8.5 hr.

199 Cold ischemia time was a predictor of DGF independently

200 Cold ischemia time was longer in those with recurrent st

201 uced the alanine aminotransferase level when cold ischemia time was longer than 6 h (P = 0.0125).

202 Cold ischemia time was not found to be an important fact

203 cold ischemia time was significantly longer (18.6 +/- 1.

204 ets expressing either P-selectin or vWF, the cold ischemia time was significantly longer (885 +/- 123

205 experienced early acute rejection, the mean cold ischemia time was significantly longer than in allo

206 Cold ischemia time was similar in the normothermia and h

207 Cold ischemia time was strongly associated with DGF, wit

208 age difference, donor gender, donor type, or cold ischemia time were comparable.

209 percent) when the potential costs of longer cold ischemia time were considered.

210 gram, because the additional costs of longer cold ischemia time were greater than the advantages of o

211 nsplanted at MELD < 18 found younger age and cold ischemia time were protective, whereas older age, l

212 Lactated Ringer's solution and 3-hr cold ischemia time were used for mechanistic investigati

213 Warm ischemia time and cold ischemia times were 38 and 466 minutes, respectivel

214 Mean cold ischemia times were less than 20 hr.

215 In CRA, donors were older, cold ischemia times were longer, and HLA matches were wo

216 lder compared with SA recipients and donors, cold ischemia times were longer, waiting times were shor

217 Cold ischemia times were similar.

218 n time (PT), retransplantation, and warm and cold ischemia times, were applied to the UNOS database.

219 milar among the groups with the exception of cold ischemia time, which was longer in the MP group com

220 tch is an attractive strategy for shortening cold ischemia time without negatively impacting transpla